Geneva Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.6M | Buy |
4,616
+33
| +0.7% | +$25.7K | 1.43% | 26 |
|
|
2025
Q1 | $3.79M | Sell |
4,583
-3,956
| -46% | -$3.27M | 1.95% | 20 |
|
|
2024
Q4 | $6.59M | Sell |
8,539
-182
| -2% | -$141K | 2.68% | 13 |
|
|
2024
Q3 | $7.73M | Sell |
8,721
-558
| -6% | -$494K | 3.35% | 11 |
|
|
2024
Q2 | $8.4M | Buy |
9,279
+1,021
| +12% | +$924K | 3.46% | 9 |
|
|
2024
Q1 | $6.42M | Sell |
8,258
-398
| -5% | -$310K | 2.83% | 12 |
|
|
2023
Q4 | $5.05M | Sell |
8,656
-428
| -5% | -$249K | 2.8% | 12 |
|
|
2023
Q3 | $4.88M | Buy |
9,084
+3,839
| +73% | +$2.06M | 3.24% | 12 |
|
|
2023
Q2 | $2.46M | Buy |
5,245
+1,653
| +46% | +$775K | 1.6% | 23 |
|
|
2023
Q1 | $1.23M | Sell |
3,592
-498
| -12% | -$171K | 1.06% | 34 |
|
|
2022
Q4 | $1.5M | Buy |
+4,090
| New | +$1.5M | 1.41% | 27 |
|
|
2022
Q2 | – | Sell |
-3,055
| Closed | -$875K | – | 68 |
|
|
2022
Q1 | $875K | Buy |
3,055
+1,555
| +104% | +$445K | 0.54% | 41 |
|
|
2021
Q4 | $414K | Buy |
+1,500
| New | +$414K | 0.2% | 77 |
|
|
2020
Q4 | – | Sell |
-30,075
| Closed | -$4.45M | – | 105 |
|
|
2020
Q3 | $4.45M | Sell |
30,075
-410
| -1% | -$60.7K | 2.72% | 11 |
|
|
2020
Q2 | $5.01M | Buy |
30,485
+5,450
| +22% | +$895K | 3.51% | 3 |
|
|
2020
Q1 | $3.47M | Buy |
+25,035
| New | +$3.47M | 4.94% | 5 |
|